ORIGINAL ARTICLE
Tumour budding – an additional prognostic factor in colorectal cancer survival
1
Department of Pathology, Prof. Dr. Cemil Taşçıoğlu Şehir Hastanesi, Istanbul, Turkey
2
Department of General Surgery, Prof. Dr. Cemil Taşçıoğlu Şehir Hastanesi, Istanbul, Turkey
3
Department of Visceral Surgery, University Clinic of Surgery “Sv. Naum Ohridski” Skopje, North Macedonia
Submission date: 2023-01-24
Acceptance date: 2023-03-15
Publication date: 2023-04-28
Corresponding author
Andrej Nikolovski
Asst. Prof. Andrej Nikolovski Department of Visceral Surgery University Clinic of Surgery “Sv. Naum Ohridski” Bul. 11 Oktomvri 53, 1000 Skopje North Macedonia
Asst. Prof. Andrej Nikolovski Department of Visceral Surgery University Clinic of Surgery “Sv. Naum Ohridski” Bul. 11 Oktomvri 53, 1000 Skopje North Macedonia
Pol J Pathol 2023;74(1):36-41
KEYWORDS
TOPICS
ABSTRACT
Tumour budding (TB) in cancer is a phenomenon of tumour cells forming clusters, and it is associated with an epithelial-mesenchymal transition into the extracellular matrix of the tumour. It has been shown that the presence of TB in colorectal cancer (CRC) is associated with worse overall survival, higher possibility for vessel invasion, lymph node involvement, and distant metastases appearance.
In this retrospective study TB presence in operated patients for CRC is analysed. In the data from 81 patients, 26 presented with TB.
Analysis revealed high statistical significance of the effect of TB presence on the number of metastatic lymph nodes, and the lymphovascular and perineural invasion. A statistically meaningful correlation was found between the presence of TB and CRC survival (p = 0.016). Patients with right-sided colon cancer presented with worse overall survival (p = 0.011). The patients who presented lymph node metastases and TB presence had worse overall survival (p = 0.026 and p = 0.021, respectively).
Tumour budding, tumour location, and age over 64 years are found to be the independent prognostic factors in CRC patients. Tumour budding is an important prognostic factor in CRC patients that will contribute to treatment. Pathological examination must consider TB in detail.
In this retrospective study TB presence in operated patients for CRC is analysed. In the data from 81 patients, 26 presented with TB.
Analysis revealed high statistical significance of the effect of TB presence on the number of metastatic lymph nodes, and the lymphovascular and perineural invasion. A statistically meaningful correlation was found between the presence of TB and CRC survival (p = 0.016). Patients with right-sided colon cancer presented with worse overall survival (p = 0.011). The patients who presented lymph node metastases and TB presence had worse overall survival (p = 0.026 and p = 0.021, respectively).
Tumour budding, tumour location, and age over 64 years are found to be the independent prognostic factors in CRC patients. Tumour budding is an important prognostic factor in CRC patients that will contribute to treatment. Pathological examination must consider TB in detail.
REFERENCES (28)
1.
Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer – ready for diagnostic practice? Hum Pathol 2016; 47: 4-19.
2.
Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol 2017; 30: 1299-1311.
3.
Rogers AC, Winter DC, Heeney A, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer 2016; 115: 831-840.
4.
Zlobec I, Lugli A. Tumour budding in colorectal cancer: molecular rationale for clinical translation. Nat Rev Cancer 2018; 18: 203-204.
5.
Chen K, Collins G, Wang H, Toh JWT. Pathological features and prognostication in colorectal cancer. Curr Oncol 2021; 28: 5356-5383.
6.
Van Wyk HC, Roseweir A, Alexander P, et al. The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer. Ann Surg Oncol 2019; 26: 4397-4404. de Mello ES, Faraj SF, al. Prognostic significance of poorly differentiated clusters and tumor budding in colorectal liver metastases. J Surg Oncol 2018; 117: 1364-1375.
7.
Slik K, Blom S, Turkki R, et al. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer. J Pathol Clin Res 2019; 5: 63-78.
8.
Mehta A, Goswami M, Sinha R, Dogra A. Histopathological significance and prognostic impact of tumor budding in colorectal cancer. Asian Pacific J Cancer Prev 2018; 19: 2447-2453.
9.
Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005; 48: 1597-1602.
10.
Hu J, Yan WY, Xie L, et al. Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer. Medicine (Baltimore) 2016; 95: e5649.
11.
Graule J, Uth K,Fischer E, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics 2018; 10: 120.
12.
Graham RP, Vierkant RA, Tillmans LS, et al. Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol 2015; 39: 1340-6.
13.
Patients H, Ii S, Kanazawa CH, Ohkura MDY, Watanabe MDM. Tumor budding as an index to identify colon. Cancer 2008; 572: 568-572.
14.
Koelzer VH, Assarzadegan N, Dawson H, Mitrovic B, Grin A. Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience. J Pathol Clin Res 2017; 3: 171-178.
15.
Ozer SP, Barut SG, Ozer B, Catal O, Sit M. The relationship between tumor budding and survival in colorectal carcinomas. Rev Assoc Med Bras 1992; 65: 1442-1447.
16.
Satoh K, Nimura S, Aoki M, et al. Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met. Cancer Sci 2014; 105: 1487-1495.
17.
Gao Z, Cao H, Xu X, Wang Q, Wu Y, Lu Q. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes. World J Surg Oncol 2021; 3: 1-15.
18.
Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res 2008; 28: 1831-1836.
19.
Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33: 134-141.
20.
Cappellesso R, Luchini C, Veronese N, et al. Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. Hum Pathol 2017; 65: 62-70.
21.
Ong MLH, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg 2016; 8: 179.
22.
Petrelli F, Pezzica E, Cabiddu M, et al. Tumour budding and survival in stage II colorectal cancer: a systematic review and pooled analysis. J Gastrointest Cancer 2015; 46: 212-218.
23.
Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum 1993; 36: 627-635.
24.
Zlobec I, Bächli M, Galuppini F, et al. Refining the ITBCC tumor budding scoring system with a ‘zero-budding’ category in colorectal cancer. Virchows Arch 2021; 479: 1085-1090.
25.
Fujiyoshi K, Väyrynen JP, Borowsky J, et al. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine 2020; 57: 102860.
26.
Basile D, Broudin C, Emile JF, et al. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Ann Oncol 2022; 33: 628-637.
27.
Kakar S, Shi C, Berho ME, et al. Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum (V4.0.0.1).
28.
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. Springer, Switzerland 2017.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
